Occlusal stabilization splint for patients with temporomandibular disorders: Meta-analysis of short and long term effects by Kuzmanović-Pfićer, Jovana et al.
RESEARCH ARTICLE
Occlusal stabilization splint for patients with
temporomandibular disorders: Meta-analysis
of short and long term effects
Jovana Kuzmanovic Pficer1*, Slobodan Dodic2, Vojkan Lazic2, Goran Trajkovic3,
Natasa Milic3☯, Biljana Milicic1☯
1 Department for Medical Statistics and Informatics, School of Dental Medicine University of Belgrade,
Belgrade, Serbia, 2 Department of Prosthodontics, School of Dental Medicine University of Belgrade,
Belgrade, Serbia, 3 Department for Medical Statistics and Informatics, School of Medicine University of
Belgrade, Belgrade, Serbia
☯ These authors contributed equally to this work.
* jovana57@yahoo.com
Abstract
Background
Psychological discomfort, physical disability and functional limitations of the orofacial sys-
tem have a major impact on everyday life of patients with temporomandibular disorders
(TMDs). In this study we sought to determine short and long term effects of stabilization
splint (SS) in treatment of TMDs, and to identify factors influencing its efficacy.
Methods
MEDLINE, Web of Science and EMBASE were searched for randomized controlled trials
(RCTs) comparing SS to: non-occluding splint, occlusal oral appliances, physiotherapy,
behavioral therapy, counseling and no treatment. Random effects method was used to sum-
marize outcomes. The effect estimates were expressed as odds ratio (OR) or standardized
mean difference (SMD) with 95% confidence interval. Subgroup analyses were carried out
according to the use of Research Diagnostic Criteria (RDC/TMD) and TMDs origin. Strength
of evidence was assessed by GRADE. Meta-regression was applied.
Results
Thirty three eligible RCTs were included in meta-analysis. In short term, SS presented posi-
tive overall effect on pain reduction (OR 2.08; p = 0.01) and pain intensity (SMD -0.33; p =
0.02). Subgroup analyses confirmed SS effect in studies used RDC/TMD and revealed its
effect in patients with TMDs of muscular origin. Important decrease of muscle tenderness
(OR 1.97; p = 0.03) and improvement of mouth opening (SMD -0.30; p = 0.04) were found.
SS in comparison to oral appliances showed no difference (OR 0.74; p = 0.24). Meta-regres-
sion identified continuous use of SS during the day as a factor influencing efficacy (p =
0.01). Long term results showed no difference in observed outcomes between groups. Low
quality of evidence was found for primary outcomes.
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Conclusion
SS presented short term benefit for patients with TMDs. In long term follow up, the effect is
equalized with other therapeutic modalities. Further studies based on appropriate use of
standardized criteria for patient recruitment and outcomes under assessment are needed to
better define SS effect persistence in long term.
Background
Psychological discomfort, physical disability and functional limitations of the orofacial system
have a major impact on everyday life of patients with temporomandibular disorders (TMDs)
[1–3]. Epidemiological studies indicate that approximately 10% to 15% of the general popula-
tion has TMDs; while 5% of the respondents require therapy [4, 5]. The highest prevalence of
TMDs is found in subjects between 18 and 45 years of age and is more common in women [6].
The causes of TMDs are not always clearly defined, nor it is known if they originate from the
joint structures or muscles, thus influencing decision making in establishing proper diagnosis
[7, 8]. Etiological factors are numerous, insufficiently studied, and may alone or in combina-
tion contribute to the development of TMDs [9, 10].
A popular dispute regarding occlusal treatments in treating TMDs has an everlasting his-
tory and does not seem to be calming down. The fact that nearly 100 million people have
TMDs in the USA [11] and that approximately 3 million splints are made per year, at a cost of
$990 million only in the United States [12], demonstrate the need for further research of this
topic. American Association for Dental Research (AADR) has given a policy statement [13],
that managing TMDs should be evidence-based and aiming to provide therapy with the great-
est potential for long term symptoms relief. There are many different therapeutic options that
can eliminate the symptoms in muscles and jaw joints, and these include the usage of occlusal
oral appliances, pharmacological therapy, physical therapy, cognitive-behavioral therapy
(CBT), counseling and self-care management or its combinations. One of the preferred thera-
pies for treating patients with TMDs is stabilization splint (SS), a flat occlusal plate made of
hard acrylic or polycarbonate material. SS is designed to promote occlusal stability[14] and
decrease muscles tension [15].
Conducted randomized controlled trials (RCTs) assessing TMDs presented conflicting
results [16–21], while gathered data in systematic reviews didn’t provide clear evidence
whether the use of SS is justified in treating TMDs [7, 12, 22–26]. More importantly,
approaches used for evaluation of SS in published reviews differ significantly. Several meta-
analyses evaluated the efficacy of SS versus individual treatment [12, 24, 25]. Fricton at al. pre-
sented results in favor of SS, but pointed out limitations regarding the type of TMDs origin
and duration of therapy [24]. Al Ani et al. provided weak evidence of SS efficacy for muscular
pain dysfunction syndrome in short and long term [25]. Ebrahim et al. investigated occlusal
appliances versus minimal treatment, using different designs of splint, and found important
difference between these groups, but they haven’t followed the effect of SS in time [12]. Main
reasons that undermined validity of mentioned meta-analyses occurred due to large heteroge-
neity of included populations and type of TMDs origin, lack of using strict criteria such as
established Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD or
DC/TMD) [27, 28] for studies inclusion [1, 24, 26], and inconsistent assessment of follow up
period [12, 24]. Lack of identified factors influencing SS efficacy is also present in the literature
[1, 23, 24]. In this study we sought to determine short and long term effects of SS through
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systematic review and meta-analysis of all eligible RCTs using SS as an intervention, to assess
these findings on studies used only RDC/TMD criteria, and to identify factors influencing SS
efficacy in reducing signs and symptoms of TMDs.
Materials and methods
Search methods for identification of studies
The search for relevant studies in any language was conducted up to October 2016. The follow-
ing databases were searched individually but revised appropriately for each database: MED-
LINE (1966 to the present), Web of Science (1980 to the present) and EMBASE (1966 to the
present). Journals considered relevant for TMDs were examined to identify the primary stud-
ies. Also, references from primary studies, reviews and systematic reviews were looked into for
relevant data. The search strategy used a combination of controlled vocabulary (MESH) and
free text terms (controlled vocabulary is given in upper case type and free text terms in lower
case): TEMPOROMANDIBULAR JOINT DISORDERS OR temporomandibular disorders
OR CRANIOMANDIBULAR DISORDERS OR myofacial pain OR myofascial pain OR orofa-
cial pain OR FACIAL PAIN OR HEADACHE AND stabilization splint OR OCCLUSAL
SPLINTS OR occlusal appliance OR splint therapy (S1 File). The process of reporting was con-
ducted using PRISMA Statement (Preferred reporting items for systematic review and meta-
analysis protocols) [29] (S1 Checklist).
Criteria for considering studies for this review
Types of studies. All RCTs or quasi-randomized controlled trials in which SS was com-
pared to different control group were selected for this meta-analysis. Abstracts were not con-
sidered in the study.
Studied population. TMD patients with more than one of following symptoms or signs
were included as studied population: myofascial pain and /or pain in the TMJ, myofascial pain
and/or pain in the TMJ on palpation, muscles tenderness, limitation or deviation in mandibu-
lar range of motion, limited mouth opening with/ without reduction, presence of sound effects
in TMJ, headache or earache. Patients with systemic diseases and comorbidities were excluded.
Patients who had unsuccessfully undergone splint therapy or other TMD treatments in the
past were not excluded.
Types of interventions. SS (Michigan splint, Tanner appliance, the Fox appliance, centric
relation appliance) compared to control group including any of following treatments was eval-
uated: non-occluding splint, occlusal oral appliances, physical therapy, behavioral therapy,
minimal treatment group (exercise and counseling) and no treatment. Combinations of treat-
ments were also analyzed.
Types of outcome measures. Outcome variables were evaluated in short ( 3 months)
and long term follow up (>3 months). The primary outcomes that were analyzed were:
1. Pain reduction measured categorically and
2. Pain intensity estimated by any recognized validated pain scale: visual analogue scale
(VAS), numeric rating scale (NRS), characteristic pain intensity (CPI) and pain severity
score (PSS)
Subgroup analyses were carried out for both primary outcomes based on the use of
Research Diagnostic Criteria (RDC/TMD) and TMDs origin (muscular, articular or both).
Separate analyses were performed according to treatment group, i.e. non-occluding splint and
occlusal oral appliances use.
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Secondary outcomes were: maximum mouth opening (mm), muscle tenderness reduction,
temporomandibular joint (TMJ) lateral and posterior tenderness reduction and depression
(Modified Symptom Checklist 90-revised (SCL-90R) instruments from Axis II RDC/TMD
and Center for Epidemiologic Studies-Depression scale (CES-D)).
Data collection and analysis
Selection of studies. All relevant studies were assessed and evaluated by two reviewers
using the previously defined criteria. Two independent reviewers (JKP and SD) read and ana-
lyzed titles and abstracts. Disagreements were solved by a third author (BM).
Data extraction and management. Data extraction was conducted by two independent
authors (JKP and SD) and supervised by third author (BM). Authors agreement were
appraised using Kappa statistics. Agreement was accomplished (Kappa: 0.75–0.78). The
reviewers used standardized predefined form, thus ensuring straight forward manner in
extracting data from each eligible study for study methods (randomization procedure, method
of allocation, blindness, design and duration), participants (sample size, age, gender, diagnos-
tic criteria, origin of TMDs, TMDs symptoms duration, pain intensity on VAS before therapy,
length of SS use during the day and the presence of dropouts), the type of interventions and
the primary and secondary outcomes that were observed.
Assessment of risk of bias in included studies. All included studies were evaluated in
consent with the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
[30]. The risk of bias was assessed by two reviewers (JKP and NM) using the Cochrane Colla-
boration’s tool with response options of "Low risk" "Unclear risk" "High risk" for following cri-
teria: sequence generation, allocation concealment, blinding, incomplete outcome date,
reporting bias and other biases. Inconsistencies between reviewers were resolved by consensus
and discussion.
Measures of treatment effect. For dichotomous outcome, the estimate of the effect of
interventions was expressed as odds ratio (OR) together with 95% confidence intervals (95%
CI). Standardized mean difference (SMD) and 95% CI were used for continuous outcomes.
Dealing with missing data. When necessary, the authors from primary studies were
asked for information about missing data. When there was no response, this was addressed in
the assessment of risk of bias.
Assessment of heterogeneity. Cochran q test for heterogeneity was performed for each
meta-analysis (Chi square statistic). In addition, extent of inconsistency of treatment effects
across trials were measured (I2 statistic; the percentage of total variance across studies that is
due to heterogeneity rather than chance).
Assessment of reporting biases. Publication bias was appraised using the symmetry of
funnel plots.
Methodological quality assessment. Jadad score was used to evaluate the quality of the
studies [31].
Strength of evidence. Summary of Finding (SoF) table was created to assess the strength
of the evidence in results using GRADEpro (Version 2016, McMaster University, 2014).
Data synthesis. Meta-analysis was performed in accordance with the rules adopted by the
Cochrane Collaboration—Cochrane Reviewer’s Handbook [32]. We used random effects
method to summarize outcomes of interest. For each endpoint, a separate forest plot was
described demonstrating OR or SMD as a box and 95% CI as whiskers on both sides of the
box with the size of the box corresponding to the weight of each trial. Summary effect mea-
sures (OR or SMD) are also calculated and presented. All statistical analyses were performed
using The Cochrane Collaboration Review Manager (RevMan), version 5.3 (The Cochrane
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Collaboration, Oxford, England). Univariate meta-regression model was performed for OR
and MD as dependent variables. Meta-regression was conducted using R language and envi-
ronment for statistical computing (R package version 3.8–0.; metafore package).
Results
Studies characteristics
Thirty three eligible RCTs were included in meta-analysis. The study selection process is pre-
sented in Fig 1. Ten studies had control group with non-occluding splint [17, 19, 33–40]. Nine
studies compared SS with occlusal appliances [16, 18, 20, 41–46]. Five studies had control
group with physical therapy [47–51]. Four studies compared SS vs. behavioral treatment [52–
55]. Three studies included minimal treatment (exercise and counseling) [21, 46, 56], and one
study used counseling as control group [45]. Seven studies had no treatment as control group
[44, 50, 51, 54, 57–59]. Six studies had two control groups [44–46, 50, 51, 54]. Six studies were
followed for short and long term outcomes [16, 46, 52–55]. The total number of included par-
ticipants was 1779, which were divided to 848 in SS group and 931 patients in control group.
Overviews of included studies (S1 Table) and references of excluded studies (S2 File) for this
review are shown in supporting material.
Methodological quality assessment. The quality of the studies was assessed using the
Jadad score. The overall mean score was 3.13. Five studies showed high methodological quality
and achieved 5 points (S1 Table).
Risk of bias. Fig 2 shows risk of bias as percentages across all included studies. More than
30% had unclear risk for selection bias (random sequence generation and allocation conceal-
ment). Around 80% were high risk for performance bias. 21 RCTs were single blinded for per-
sonnel and assessed as high risk, while six studies weren’t blind nor for participants nor
personnel. Six studies were double blinded RCTs. In blinding of outcome assessment (detec-
tion bias) 15% of studies had high risk. The funnel plots suggest no publication bias for pain
reduction and pain intensity at short term (S1 and S2 Figs).
Strength of evidence. Gathered information regarding quality of included studies is pre-
sented in SoF table (S2 Table). The evaluation of results for two primary outcomes, followed
both in short and long term, showed low quality. Assessment of secondary outcomes in short
term (muscle tenderness reduction, TMJ lateral and posterior tenderness reduction, maximum
mouth opening and depression) presented moderate quality.
Data synthesis
Primary outcomes in short term follow-up. Pain reduction. In short term, SS presented
positive overall effect on pain reduction (OR 2.08; 95% CI [1.19, 3.63]; p = 0.01; I2 = 66%),
based on 16 identified studies evaluating this outcome, with a total of 848 participants. Sub-
group analysis revealed that in studies using RDC/TMD, SS had positive effect on pain reduc-
tion (OR 2.52; 95% CI [1.15, 5.52]; p = 0.02; I2 = 64%), but not for studies that didn’t use RDC/
TMD (OR 1.74; 95% CI [0.76, 4.01]; p = 0.19; I2 = 70%) (Fig 3). The pooled results from 10
studies showed significant difference between SS and control group in patients with TMDs of
muscular origin (OR 2.95; 95% CI [1.42, 6.15]; p = 0.004; I2 = 66%) (Fig 4). Six studies evalu-
ated SS in comparison to non-occluding splint, and pointed out significant effect of SS (OR
4.18; 95% CI [2.17, 8.03]; p<0.0001; I2 = 16%), while comparison of SS versus occlusal oral
appliances showed no difference between groups (based on 6 included studies) (OR 0.74; 95%
CI [0.45, 1.22]; p = 0.24; I2 = 0%) (Fig 5).
Pain intensity. Fifteen identified studies evaluated pain intensity with total of 1118 partici-
pants. Ten studies used VAS, one study used NRS, while two studies each used CPI and PSS,
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Fig 1. Flow chart diagram. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi: 10.1371/journal.pmed1000097. For
more information, visit www.prisma-statement.org.
doi:10.1371/journal.pone.0171296.g001
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Fig 2. Risk of bias graph: Review authors’ judgments about each risk of bias item presented as percentages across all included
studies.
doi:10.1371/journal.pone.0171296.g002
Fig 3. Forest plot comparison: Stabilization splint vs. Control group. Pain reduction according to RDC/TMD at short term.
doi:10.1371/journal.pone.0171296.g003
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respectively. Meta-analysis demonstrated statistically significant difference between groups in
favor of the SS (SMD -0.33; 95% CI [-0.61, -0.05]; p = 0.02; I2 = 80%) (Fig 6). Subgroup analy-
ses showed no difference in SS effect according to the use of RDC/TMD criteria (SMD -0.27;
95% CI [-0.60, 0.06]; p = 0.10; I2 = 75% for studies that used RDC/TMD; SMD -0.41; 95% CI
[-0.94, 0.13]; p = 0.14; I2 = 86% for studies that didn’t use RDC/TMD) (Fig 7). The pooled
results from 6 studies that evaluated TMDs of muscular origin showed significant difference
between groups (SMD -0.64; 95% CI [-1.17,-0.10]; p = 0.02, I2 = 88%) in favor of the SS (Fig 8).
Primary outcomes in long term follow-up. Pain reduction. Long term results showed
no difference in pain reduction between groups, based on six observed studies with total of
251 participants (OR 1.01; 95% CI [0.26, 3.96]; p = 0.99; I2 = 79%). Subgroup analyses pre-
sented the same effects both in studies that used RDC/TMD (OR 1.15; 95% CI [0.49, 2.69];
p = 0.75; I2 = 0%) and that didn’t use RDC/TMD (OR 0.86; 95% CI [0.04, 20.53]; p = 0.92;
I2 = 91%) (Fig 9).
Fig 4. Forest plot comparison: Stabilization splint vs. Control group. Pain reduction according to TMDs origin at short term.
doi:10.1371/journal.pone.0171296.g004
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Pain intensity. Seven studies with 553 participants followed the long-term effects of SS ther-
apy on pain intensity, out of which two studies used VAS, CPI and PSS, while one study used
NRS. There was no statistically significant difference between SS and control group (SMD
-0.03 [-0.34, 0.29]; p = 0.86; I2 = 66%) (Fig 10). Subgroup analyses showed the same effects
both in studies that used RDC/TMD (SMD -0.14 [-0.50, 0.22]; p = 0.44; I2 = 68%) and that
didn’t use RDC/TMD (SMD 0.31 [-0.10, 0.73]; p = 0.14; I2 = 0%) (Fig 11).
Secondary outcomes in short and long term follow-up. Muscle tenderness reduction.
Significant decrease of number of patients with muscle tenderness was found for SS group in
short term, based on four studies with 194 participants (OR 1.97; 95% CI [1.05, 3.68]; p = 0.03;
I2 = 0%) (S3 Fig).
TMJ lateral and posterior tenderness reduction. Results based on five studies with 270 par-
ticipants showed no important difference between compared groups in short term (OR 1.05;
95% CI [0.53, 2.08]; p = 0.89; I2 = 15%) (S4 Fig).
Maximum mouth opening. Assessing the results from seven studies with 298 participants,
SS showed significant effect compared to control group (SMD -0.30; 95% CI [-0.59, -0.01];
Fig 5. Forest plot comparison: Stabilization splint vs. Control group. Pain reduction according to individual treatments at short term.
doi:10.1371/journal.pone.0171296.g005
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p = 0.04; I2 = 33%) (S5 Fig). In evaluating the long term effect, 3 included studies showed no
significant difference between SS intervention and control group (SMD -0.12; 95% CI [-0.44,
0.21]; p = 0.47; I2 = 0%) (S6 Fig).
Depression. In short term, five studies with 290 participants assessed the effect of SS on
depression. Two studies used CES-D scale, while 3 studies used SCL-90R scale. Results showed
no important difference between compared groups (SMD -0.09; 95% CI [-0.44, 0.27]; p = 0.63;
I2 = 56%) (S7 Fig). Long term results based on five studies with 243 participants (2 studies
used CES-D scale and three studies used SCL-90R scale) pointed out statistically significant
difference between SS and control (SMD -0.30; 95% CI [0.05, 0.56]; p = 0.02; I2 = 0%) in favor
of the control group (S8 Fig).
Meta-regression. The influence of independent factors on the effect size of SS for pain
reduction and pain intensity was assessed by meta-regression analysis in short time follow-up.
Univariate meta-regression model was performed for OR and SMD as dependent variables.
The following factors were examined: age, sex, therapy duration, TMDs symptoms duration,
pain intensity on VAS before therapy, length of SS use during the day and the presence of
Fig 6. Forest plot comparison: Stabilization splint vs. Control group. Pain intensity according to numeric scales at short term.
doi:10.1371/journal.pone.0171296.g006
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dropouts. After analysis of factors for both primary outcomes, length of use SS during the day
was singled out as significant factor for pain reduction (meta-regression coefficient was 1.73
(SE 0.69; p = 0.011)). These results presented that the effect of SS was better in patients in
which splint was present for 24 hours than in patients who used it only during the night (S3
Table).
Discussion
Over the years, SS became the most frequent therapeutic choice for the treatment of TMDs,
and the most evaluated one [60]. This meta-analysis observed RCTs for short and long term
effects of SS compared to control group, and further investigated the role of validated diagnos-
tic system in establishing therapy effect, while determining adequate course of treatment for
particular origin of TMDs. Effect of SS was determined by the means of pain assessment, mea-
sured as the presence of pain reduction and/or estimated pain intensity. Pain reduction was
defined as an improvement or reduction in signs and symptoms at the end of the treatment,
while, numeric scales (such as VAS, NRS, CPI and PSS) are used for determining the pain
intensity. Two of these numeric scales (VAS and NRS) represent pain intensity at the end of
therapy, while CPI and PSS show levels of multiply measured pain intensity over the time.
Using SMD in data synthesis, we were able to compare data gathered with these four different
scales. Besides the pain assessment, the effect of SS on maximum mouth opening, muscle and
TMJ tenderness and depression was also evaluated in order to gain additional insight in the
overall success of SS therapy.
Fig 7. Forest plot comparison: Stabilization splint vs. Control group. Pain intensity according to RDC/TMD at short term.
doi:10.1371/journal.pone.0171296.g007
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Regarding the pain reduction in short term evaluation (follow up less than 3 months), 16
studies were included, out of which 8 used RDC/TMD and 8 studies didn’t use these criteria.
The overall effect presented significantly better results for SS and results of subgroup analysis
revealed the same effect in studies that used RDC/TMD as validated diagnostic system for
defining TMDs. Further, pooled results of meta-analysis based on 15 studies measuring pain
intensity in short term were also in favor of SS.
A critical point was made by reviewers of different studies suggesting that patients with
muscle problems should be separated from those with TMJ problems in future research [7,
61]. However, the most of published studies included all possible patient populations, sorting
them afterwards to observe weather some of the displayed symptoms were affected by the
given therapy [62]. Dealing with this issue, we conducted a seperate subgroup analysis accord-
ing to TMDs origin to deeper inspect the effect of SS in different patient population. A signifi-
cant difference in favor of SS for both primary outcomes was demonstrated in studies with
TMDs of muscular origin.
In order to further investigate SS efficacy we carried out meta-analysis using different indi-
vidual therapeutic modalities as a control group. First, comparison with the non-occluding
splint use (type of placebo splint) demonstrated significant difference between those in short
term. SS showed better effect in pooled results of all studies examining pain reduction, which
is in accordance with the results of Fricton et al. [24], but in contrast to Al Ani et al. that
Fig 8. Forest plot comparison: Stabilization splint vs. Control group. Pain intensity according to TMDs origin at short term.
doi:10.1371/journal.pone.0171296.g008
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Fig 9. Forest plot comparison: Stabilization splint vs. Control group. Pain reduction at long term.
doi:10.1371/journal.pone.0171296.g009
Fig 10. Forest plot comparison: Stabilization splint vs. Control group. Pain intensity on according to numeric scales at long term.
doi:10.1371/journal.pone.0171296.g010
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presented no difference between the groups [25]. To the best of our knowledge, this is the first
meta-analysis that compared SS with other oral occlusal appliances for pain reduction, which
presented no difference between the therapy groups. This indicates that patients with TMDs
besides SS may benefit from other occlusal appliances in reducing symptoms of TMDs. This
conclusion may support the further research of the effect of occlusal therapy in more well-
designed RCTs in order to gain clearer results of possible effects of SS as well as other occlusal
therapies in treatment of TMDs. Meta-regression performed to determine the influence of dif-
ferent independent factors on SS efficacy, identify only the continuous use of SS (24 hours a
day) as contributing factor in reducing the symptoms of TMDs. Based on the results, wearing
the splint 24 hours per day stabilizes jaw position resulting in occlusal stability.
In an evaluation of the long term effects of therapy, our results demonstrated that there
were no significant differences between SS and control group. In total, 6 studies followed the
effect for pain reduction, while 7 studies followed pain intensity. Subgroup analyses presented
the same effects both in studies that used RDC/TMD and that didn’t use RDC/TMD. Just to
clarify, all studies didn’t use the same time frame for tracking the effect of SS, nor they used
same timetable of wearing the splint during the day. For pain reduction outcome, 2 studies fol-
lowed patients for 6 months and in that time patients wore splint during the night [20, 58].
Four studies followed participants for 1 year, where in one study patients wore splint during
the course of therapy only by night [57], 2 studies where approximately 50% of patients wore
splint during the night [16, 36], while in one study 47% of participants used splint several
times in a week [19]. Furthermore, for pain intensity, 4 studies followed the effect of therapy
over 6 months. One study estimated wearing a splint at all times during the therapy [52], two
studies did not wear splint upon completion of short-term therapy [53, 54], while in one study
participants continued to wear splint by night [21]. 3 studies followed the SS effect for a year
where in one study patients wore splint only during short term treatment [55], while in two
studies splint was worn at night by 50% of participants [40, 46]. Taking into account effects for
both short and long term therapies, the overall results showed that SS is more effective in treat-
ing patients with TMDs in short term period, while the long term effect of SS is equalized with
other therapeutic modalities.
Fig 11. Forest plot comparison: Stabilization splint vs. Control group. Pain intensity according to RDC/TMD at long term.
doi:10.1371/journal.pone.0171296.g011
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Observing the secondary outcomes for short term therapies, results demonstrated benefit
for SS group in terms of muscle tenderness reduction and improved maximum mouth open-
ing. Results for TMJ lateral and posterior tenderness reduction and depression presented no
important difference between observed groups. In long term follow up of SS effect, similar
results were obtained between compared groups for maximum mouth opening, while signifi-
cant difference was found for depression in favor of the control group. Splint also increases
vertical dimension of occlusion which relaxes jaw muscles. Our meta-analysis confirmed, eval-
uating pain outcomes and through reduction of muscle tenderness and maximum mouth
opening, that patients with myogenous TMDs may have significant benefit from SS.
Quality assessment
Jadad score used in assessing the methodological quality of RCTs included in meta-analysis
showed moderate quality of included RCTs studies. Main cause for this estimation was the
lack of double blinded design of RCTs. Furthermore, assessment of risk of bias also presented
flaws of blinding process. More than 80% of studies were high risk for performance bias, while
15% of studies were high risk for blinding of outcome assessment (detection bias). Publication
bias, as form of selection bias showed no important asymmetry in none of the observed out-
comes (pain reduction and pain intensity) in the funnel plots.
Strength of evidence
Evaluation of primary outcomes using SoF table presented low quality of evidence for primary
outcomes in both short and long term period. The first reason for this is the presence of risk of
bias which was estimated as serious due to lack of blinding process, unclear allocation conceal-
ment and random sequence generation. The second reason for low quality of evidence is mod-
erate heterogeneity. Assessment of secondary outcomes shows moderate quality of evidence in
short term (S2 Table).
Comparison with other reviews
Some of the most prominent systematic reviews presented different results for the effect of SS
in relation to other types of therapy. There are a number of limitations that challenge the inter-
pretation of the results of these meta-analyses. Careful attention to these caveats is not only the
key for critical evaluation of the literature, but it also has implications for treatment of patients,
and for the development and implementation of practice guidelines. There are several system-
atic reviews and meta-analysis that analyzed effect of SS with other therapies separately, while
other combined SS with other therapeutic modalities [1, 12, 24–26]. Few important issues are
distinguishing our meta-analysis from others. First of all, in order to evaluate more accurately
the effect of SS, we used two primary outcomes for pain assessment followed by several sec-
ondary outcomes. This provided more valid data of SS efficacy. Also, we wanted to investigate
the importance of using validated diagnostic system and its influence on overall effect of SS.
Further, dividing studies according to TMDs origin enabled deeper insight in which popula-
tion should benefit more from wearing SS. Fricton et al. in their systematic review demon-
strated the advantage of SS versus non-occluding splint and minimal treatment for pain
reduction [24]. A systematic review of Al-Ani et al. showed no significant difference in the
therapeutic effect of SS versus non-occluding splints for pain outcome. They also presented lit-
tle evidence for SS compared with other forms of therapy [25]. Furthermore, there are system-
atic reviews that evaluated effects of different types of appliances without separating SS
exclusively. Ebrahim et al. in their meta-analysis found significant results comparing the effect
of different types of splints for pain reduction with minimal treatment or no treatment,
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without separating the studies on short term and long term [12]. Results from systematic
review of Aggarwal et al. showed comparison of psychosocial therapy versus usual treatment
and presented significantly better results for usual treatment (occlusal splint, exercise and
drugs) versus CBT in short term for pain outcome. In long term, CBT has an advantage over
the usual treatment [26]. According to a recent review on this topic, study of Roldan-Barazza
et al. showed that psychosocial therapy achieves better effects for pain outcome for long term,
while in short term there is no difference [1].
Our results confirmed that the effect of SS for pain outcome in short term is significantly
better than control group, while for long term studies the effect fades away. Small number of
studies addressed this issue concerning the long term effect of SS and continued following
patients habits of wearing splint. All of them presented that approximately 50–60% of patients
continued wearing splint during the night [16, 36], while others ceased wearing the splint
completely [53, 54]. Roldan-Baraza et al. showed that the usual treatment had greater efficacy
for mouth opening, which was also confirmed by our results [1]. Ebrahim et al. in his study
also analyzes the effect of therapy on depression and demonstrates that there is no significant
difference between compared groups [12], while Aggarwal et al. presented statistically signifi-
cant difference between psychosocial treatment and usual treatment in long term studies [26].
Our results indicate that there is no significant difference between the SS and other therapies
for depression in the short term, however results are in favor of the control group for long
term studies. These results showed that SS can affect the psyche of patients prone to depression
in short term, but in long term other therapies are better for this particular population.
Advantages and limitations of the study
The advantage of this meta-analysis is the isolation of SS effect and its comparison to other
therapies altogether, in short and long term period. Subgroup analyses of outcomes based on
RDC/TMD are another advantage of the study. Separation of included studies whether they
used RDC/TMD for pain assessment or not, provided more valid results of our analysis and
presented the importance of these criteria in estimation of observed outcomes. This was con-
firmed using CPI for pain outcome and SCL-90R for depression. Also, subgroup analyses by
diagnosis and different control groups gave an additional insight into the SS effect in different
subpopulations and treatment strategies. Finally, meta-regression provided better insight into
the factors influencing SS efficacy.
Limitation of this meta-analysis is the presence of heterogeneity between pooled studies for
primary outcomes. Comparison of SS with the control group leads to a moderate or high het-
erogeneity. This resulted in low quality of evidence for primary outcomes in both short and
long term period. The lack of data in all studies was a limitation of meta-regression. Low qual-
ity of some studies may influence the overall results, and at the same time overconfidence may
occur in pain assessment causing more positive results than they actually are.
Recommendations
The overall results of this meta-analysis pointed out that in future studies investigators should
use clearly defined criteria for assessing efficacy of therapeutic modalities for treating TMDs. It
is necessary to use the appropriate study design, i.e. RCTs to determine the efficacy of therapy
under assessment, which should be conducted according to the relevant reporting guidelines
(CONSORT Statement) [63]. The importance of randomization, allocation concealment and
blinding process in these studies should be clearly defined. Beside the well-conducted RCTs,
investigators should pay attention not only on short term effects but also insist in pursuing
long term therapy effects. Studied population should be based on standardized criteria for
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diagnosing of TMDs (RDC/TMD or DC/TMD). The sample size should be determined a pri-
ori for each study in order to be able to identify the true effect of the treatment. Lastly, appro-
priate scale measurement for pain outcome should be established using characteristic pain
intensity from RDC/TMD criteria and used in straight-forward manner for the assessment of
therapy effect. In addition, presented results should provide all the information needed for sec-
ondary analysis.
Conclusion
SS may have a significant role in treating TMDs in short term, while its effect is equalized with
other therapeutic modalities in long term follow up. Further studies based on appropriate use
of standardized criteria for patient recruitment and outcomes under assessment are needed to
better define SS treatment modalities that may influence its effect persistence in long term.
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